Anthony Daniyan
Overview
Explore the profile of Anthony Daniyan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dao T, Xiong G, Mun S, Meyerberg J, Korontsvit T, Xiang J, et al.
Blood
. 2023 Dec;
143(6):507-521.
PMID: 38048594
Chimeric antigen receptor T-cell (CAR T) therapy has produced remarkable clinical responses in B-cell neoplasms. However, many challenges limit this class of agents for the treatment of other cancer types,...
2.
Arcila M, Patel U, Momeni-Boroujeni A, Yao J, Chan R, Chan J, et al.
J Mol Diagn
. 2023 Jun;
25(9):634-645.
PMID: 37330049
Although in vivo engraftment, expansion, and persistence of chimeric antigen receptor (CAR) T cells are pivotal components of treatment efficacy, quantitative monitoring has not been implemented in routine clinical practice....
3.
Bewersdorf J, Derkach A, Gowda L, Menghrajani K, DeWolf S, Ruiz J, et al.
Leuk Lymphoma
. 2021 Sep;
62(14):3394-3401.
PMID: 34477024
The role of allogeneic hematopoietic cell transplant (allo-HCT) as consolidation after initial venetoclax therapy and the efficacy of venetoclax salvage therapy for relapse after allo-HCT in patients with acute myeloid...
4.
Stahl M, Narendra V, Jee J, Derkach A, Maloy M, Geyer M, et al.
Leuk Lymphoma
. 2021 Jun;
62(8):1940-1948.
PMID: 34180767
Patients with hematological malignancies are at risk for poor outcomes when diagnosed with coronavirus disease 2019 (COVID-19). It remains unclear whether cytopenias and specific leukemia subtypes play a role in...
5.
Shah G, DeWolf S, Lee Y, Tamari R, Dahi P, Lavery J, et al.
J Clin Invest
. 2020 Sep;
130(12):6656-6667.
PMID: 32897885
BACKGROUNDUnderstanding outcomes and immunologic characteristics of cellular therapy recipients with SARS-CoV-2 is critical to performing these potentially life-saving therapies in the COVID-19 era. In this study of recipients of allogeneic...
6.
Morjaria S, Zhang A, Kaltsas Md A, Parameswaran R, Patel D, Zhou W, et al.
medRxiv
. 2020 Aug;
PMID: 32817981
Background: Neutropenia is commonly encountered in cancer patients, and recombinant human granulocyte colony-stimulating factor (G-CSF, filgrastim) is widely given to oncology patients to counteract neutropenia and prevent infection. G-CSF is...
7.
Hoffman N, Tran V, Daniyan A, Ojugbele O, Pryor S, Bonventre J, et al.
Med Sci Monit
. 2006 Feb;
12(3):BR87-94.
PMID: 16501417
Background: Here, we addressed the concern that, despite the lack of overt toxicity, exposure to low levels of the common household pyrethroid pesticide, bifenthrin, could cause harm to the immune...